991 results on '"Gerber, David E."'
Search Results
2. Transferring care to enhance access to early-phase cancer clinical trials: Protocol to evaluate a novel program
3. AXL Inhibitors: Status of Clinical Development
4. Characteristics of Lung Cancer Patients With Asymptomatic or Undiagnosed SARS-CoV-2 Infections
5. Telemedicine and Cancer Clinical Research: Opportunities for Transformation
6. A phase II clinical trial evaluating the safety and efficacy of durvalumab as first line therapy in advanced and metastatic non-small cell lung cancer patients with Eastern Cooperative Oncology Group performance status of 2
7. Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study
8. Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer
9. Antibiotic Prescriptions in Lung Cancer and Melanoma Populations: Differences With Potential Clinical Implications in the Immunotherapy Era
10. Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors
11. EGFR ligand shifts the role of EGFR from oncogene to tumour suppressor in EGFR-amplified glioblastoma by suppressing invasion through BIN3 upregulation
12. Differences in systemic immune parameters in individuals with lung cancer according to race
13. Distinct autoantibody profiles across checkpoint inhibitor types and toxicities
14. Geographic Accessibility and Completion of Initial Low-Dose CT-Based Lung Cancer Screening in an Urban Safety-Net Population
15. Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice
16. Effect of Patient Navigation on Completion of Lung Cancer Screening in Vulnerable Populations
17. Enhancing access to and diversity in cancer clinical trials through a financial reimbursement program: Protocol to evaluate a novel program
18. Prevalence And Impact of Medical Comorbidities in A Real‐World Lung Cancer Screening Population
19. Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report
20. Implementation and Uptake of Rural Lung Cancer Screening
21. Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer.
22. TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer
23. Resistance Mechanisms in ROS1-Positive Lung Cancer: New Insight into a Rare but Clinically Important Entity
24. The Joint Problem of Rheumatoid Arthritis and Lung Cancer
25. Emerging Strategies in Lung Cancer Screening: Blood and Beyond
26. Clinician Variation in Ordering and Completion of Low-Dose Computed Tomography for Lung Cancer Screening in a Safety-Net Medical System
27. Better Late Than Never: Fully Incorporating Oncology Advanced Practice Providers Into Cancer Clinical Trials
28. Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non–Small-Cell Lung Cancer (RTOG 3505)
29. Survival of women diagnosed with breast cancer and who have survived a previous cancer
30. Correction to: Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors
31. Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non–Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)
32. Prevalence and Significance of Potential Pharmacokinetic Drug–Drug Interactions Among Patients with Lung Cancer: Implications for Clinical Trials
33. Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer.
34. Tracking the Nonenrolled: Lung Cancer Screening Patterns Among Individuals not Accrued to a Clinical Trial
35. Timing, Sites, and Correlates of Lung Cancer Recurrence
36. QTc Interval-Prolonging Medications Among Patients With Lung Cancer: Implications for Clinical Trial Eligibility and Clinical Care
37. Reply to A. Grand et al
38. pan-MHC and cross-Species Prediction of T Cell Receptor-Antigen Binding
39. Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer
40. 607 TTFields therapy with an immune checkpoint inhibitor in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based therapy: histology subgroups in the pivotal LUNAR study
41. Rates of appropriate laxative prophylaxis for opioid-induced constipation in veterans with lung cancer: a retrospective cohort study
42. Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids
43. Patient and provider perspectives on delivery of oral cancer therapies
44. 21st Century Cures Act: Implementation Without Understanding Implication?
45. Increasing Numbers and Reported Adverse Events in Patients with Lung Cancer Undergoing Inpatient Lung Biopsies: A Population-Based Analysis
46. EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer
47. Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published Cases
48. Reimbursement Matters: Overcoming Barriers to Clinical Trial Accrual
49. Initial steps in creating a patient-centric addendum to clinical trial informed consent forms
50. An Updated Report on the Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer in the Surveillance, Epidemiology, and End Results Program
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.